

# Noah C Federman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3653868/publications.pdf>

Version: 2024-02-01

41  
papers

1,739  
citations

394286

19  
h-index

345118

36  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2837  
citing authors

#	ARTICLE	IF	CITATIONS
1	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
2	Current management of aneurysmal bone cysts. <i>Current Reviews in Musculoskeletal Medicine</i> , 2016, 9, 435-444.	1.3	149
3	The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. <i>Cancer Cell</i> , 2018, 33, 905-921.e5.	7.7	135
4	The Multidisciplinary Management of Osteosarcoma. <i>Current Treatment Options in Oncology</i> , 2009, 10, 82-93.	1.3	118
5	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	0.8	91
6	Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 85-92.	0.4	52
7	Tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017, 8, 8035-8042.	0.8	50
8	Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 931-939.	1.3	48
9	Alveolar soft part sarcoma in children and young adults: A report of 69 cases. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26953.	0.8	45
10	Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	0.7	39
11	Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor. <i>Sarcoma</i> , 2012, 2012, 1-11.	0.7	34
12	Alveolar Soft Part Sarcomas: Molecular Pathogenesis and Implications for Novel Targeted Therapies. <i>Sarcoma</i> , 2012, 2012, 1-9.	0.7	34
13	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 361-365.	1.2	34
14	Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133610.	1.1	30
15	Personalized chordoma organoids for drug discovery studies. <i>Science Advances</i> , 2022, 8, eabl3674.	4.7	29
16	A Mobile-Based Mindfulness and Social Support Program for Adolescents and Young Adults With Sarcoma: Development and Pilot Testing. <i>JMIR MHealth and UHealth</i> , 2019, 7, e10921.	1.8	28
17	Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets. <i>Paediatric Drugs</i> , 2014, 16, 21-28.	1.3	27
18	Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 217-224.	1.5	26

#	ARTICLE	IF	CITATIONS
19	PET/CT in Evaluating Pediatric Malignancies: A Clinician's Perspective. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1920-1922.	2.8	22
20	The genetic basis of bone marrow failure syndromes in children. <i>Molecular Genetics and Metabolism</i> , 2005, 86, 100-109.	0.5	20
21	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	17
22	Coupling Lipid Labeling and Click Chemistry Enables Isolation of Extracellular Vesicles for Noninvasive Detection of Oncogenic Gene Alterations. <i>Advanced Science</i> , 2022, 9, e2105853.	5.6	15
23	Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10010-10010.	0.8	14
24	Fetal programming and Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27461.	0.8	13
25	The Role of Social Media in Providing Support from Friends for Adolescent and Young Adult (AYA) Patients and Survivors of Sarcoma: Perspectives of AYA, Parents, and Providers. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 720-725.	0.7	9
26	[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , 2020, 10, 122.	1.1	8
27	Sclerostin expression in skeletal sarcomas. <i>Human Pathology</i> , 2016, 58, 24-34.	1.1	7
28	SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11016-11016.	0.8	6
29	Cyclin A Is a Target Gene of Activated CREB Downstream of GM-CSF Signaling That Regulates Normal and Malignant Myelopoiesis.. <i>Blood</i> , 2004, 104, 2181-2181.	0.6	6
30	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	5
31	Tâ€œAK cellâ€œoriginated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Molecular Oncology</i> , 2021, 15, 3721-3737.	2.1	5
32	Spina bifida and pediatric cancers. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 630-636.	0.3	4
33	A Case of a 15-Month-Old With Periorbital Edema and Severe Anemia. <i>Pediatrics</i> , 2020, 145, .	1.0	4
34	Novel association of familial testicular germ cell tumor and autosomal dominant polycystic kidney disease with <i>PKD1</i> mutation. <i>Pediatric Blood and Cancer</i> , 2017, 64, 100-102.	0.8	3
35	A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 525-531.	0.3	2
36	A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS10591-TPS10591.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis.. Journal of Clinical Oncology, 2019, 37, 11020-11020.	0.8	1
38	Infratemporal Fossa Ganglioneuroma in a Pediatric Patient: A Case Report and Review of Literature. Laryngoscope, 2011, 121, S337.	1.1	0
39	OUP accepted manuscript. Laboratory Medicine, 2021, , .	0.8	0
40	CREB Overexpression In Vivo Results in Increased Proliferation, Blast Transformation, and Earlier Engraftment of Myeloid Progenitor Cells.. Blood, 2004, 104, 3548-3548.	0.6	0
41	What's New in Pediatric Orthopaedic Tumor Surgery. Journal of Pediatric Orthopaedics, 2021, 41, e174-e180.	0.6	0